Overview

A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Status:
Recruiting

Trial end date:
2023-02-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy; safety and tolerability of ASP8062 compared with placebo ASP8062 as add-on therapy to buprenorphine/naloxone.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Treatments:

Buprenorphine
Buprenorphine, Naloxone Drug Combination
Naloxone